Somewhere in a freezer in Hayward, California, sits a receptor that three pharmaceutical companies couldn't get to express. Multispan got it to express. Then it built a cell line around it, validated an assay on it, and shipped it ready-to-use. This is what the company does on a Tuesday.
GPCRs — G protein-coupled receptors — are the most important drug targets almost no one outside a lab has heard of. They sit on the surface of your cells, catch signals, and relay them inward. Roughly a third of all approved medicines work by nudging one. They are also famously uncooperative: hard to express, hard to keep stable, hard to read cleanly. For a 11-person company in the East Bay, that difficulty isn't a problem. It's the entire business.
The problem they sawA target family that refuses to behave
Here is the inconvenient truth of GPCR research: the receptors that matter most are often the ones that don't survive the move from a textbook diagram to a working assay. Put a finicky receptor in the wrong cell, and you get noise. Over-express it badly, and the biology stops resembling anything in a human body. Drug hunters need numbers they can trust, and the cell line underneath those numbers decides whether they can.
You can't screen a drug against a receptor you can't reliably grow. Multispan's whole reason to exist starts there.
// The unglamorous bottleneck of modern drug discoveryMost of the industry treats cell-line generation as a step to get through. Multispan treats it as the product. The distinction sounds small. It is not. When the cell line is an afterthought, every downstream result inherits its flaws. When the cell line is the thing you obsess over, the data on the other end is finally worth reading.
The founder's betHelena Mancebo's wager on the hard stuff
In 2004, Helena Mancebo founded Multispan on a bet that sounds almost stubborn: that there was a durable business in being the company other companies call when a GPCR won't cooperate. Not the biggest market. Not the flashiest. But a deep one, and one where reputation compounds. Twenty-plus years later, the bet has the look of someone who knew exactly which corner of the field they wanted to own.
We believe GPCRs represent a largely unexplored area for therapeutic antibody development.
// Helena Mancebo, Founder & CEO, 2006It was, admittedly, an odd thing to be excited about — receptors so difficult that much of the industry quietly routed around them. But that was the point. The harder the target, the fewer the people who can serve it, and the more a specialist's library of solved problems becomes its own moat.
MULTISCREEN, and a library worth more than the sum of its vials
What Multispan actually sells is the MULTISCREEN platform: a portfolio of 600+ clonally-derived, HTS-ready stable cell lines and over 2,000 ready-to-use tools — calcium and cAMP assay kits, membrane preparations, proliferation assays. Underneath sits the company's proprietary HEx high-expression cell technology, which coaxes stubborn receptors into expressing at levels sensitive enough to read, and clean enough to believe.
MULTISCREEN cell lines
600+ clonally-derived, HTS-ready stable lines expressing human GPCRs and beyond.
HEx high-expression
Proprietary cells sensitive enough for assays, robust enough to serve as whole-cell immunogens.
Custom & CRISPR engineering
Bespoke, assay-ready cell lines built to a client's exact target and readout.
Compound & bias profiling
Profiling across up to 250 druggable GPCRs and 75 orphans, including biased-signaling and internalization assays.
The phrase the company uses for all of this is "sustainable drug discovery by making every assay count." Marketing tidiness aside, it captures something real: if the foundational reagent is sound, fewer experiments get wasted chasing artifacts. The library compounds in value precisely because each new solved receptor is one the next customer doesn't have to solve again.
The company drug hunters call when a receptor refuses to behave.
// What 20 years of repeat business buys youTwo decades, quietly
Helena Mancebo founds Multispan, Inc. in Hayward, California, betting on the hardest target family in pharmacology.
Signs a licensing agreement with Medarex to supply HEx GPCR over-expressing cell lines as whole-cell immunogens for fully-human antibody discovery.
Raises a $600K round (reported as Series B), part of roughly $1.1M total across three rounds.
Refreshes its brand and logo — the version sitting at the top of this page.
Maintains 600+ stable cell lines and 2,000+ reagents with a reputation for high client return business.
When a 600-line library does the talking
Proof, in this business, is unglamorous. It's a customer who came back. It's a receptor that finally read clean. The clearest external marker is the 2006 Medarex deal: a fully-human antibody company chose Multispan's high-expression cells as the immunogen platform for therapeutic antibody discovery. That's not a logo on a slide — it's another company staking its own pipeline on Multispan's cells.
A small team, an outsized library
Bars scaled for comparison; reagent count shown at 1/10 scale to fit. Roughly 55 stable cell lines per employee — a depth-over-headcount story. Figures from company and third-party sources; revenue estimates (~$6-7.7M) are third-party and approximate.
There's an irony worth noting. The very obscurity that makes GPCRs hard is what protects a company like Multispan. A market this specialized doesn't attract a stampede of competitors — Eurofins DiscoverX, Charles River and a handful of others circle the broader space — but the library of already-solved receptors is the kind of asset you can't shortcut your way into. You build it one stubborn clone at a time, or you don't have it.
The missionMaking every assay count
Multispan's stated aim is to fold cell engineering, assay development, and high-throughput screening into one seamless process. Stripped of the brochure language, it's a pledge about waste: in drug discovery, the cost of a misleading result isn't one bad data point — it's the months a team spends chasing it. A trustworthy cell line at the start of the pipeline is the cheapest insurance money can buy.
Four things worth knowing
- GPCRs are the target of roughly a third of all FDA-approved drugs — and Multispan specializes almost entirely in them.
- The company can profile against up to 75 "orphan" receptors — GPCRs whose natural signaling partners are still unknown.
- Its social handles are literally @MultispanGPCR. No one will accuse them of burying the lede.
- An ~11-person team maintains 600+ stable cell lines — about 55 lines per person.
The receptors aren't getting easier
Biased signaling. Receptor internalization. Native, endogenous pathways instead of artificial over-expression. The frontier of GPCR drug discovery is moving toward exactly the kind of subtlety that demands better cell biology, not more of it. As the questions get finer, the value of a foundation you can trust gets higher. That's the tailwind a specialist quietly rides.
So back to that freezer in Hayward. The receptor three companies couldn't grow is now a line in a catalog, a vial in a box, a clean number on someone else's screen. Multispan didn't cure a disease this week. It did something less visible and arguably more useful: it made the next cure a little easier to look for. Twenty years in, that's still the whole job — and they're still the ones you call.